Physician profile
Lacie D Truitt
NPI 1972881993
$3,753.08
in general payments reported to CMS, 2019-2025
10 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $110 · 2021: $1,518 · 2022: $418 · 2023: $632 · 2024: $356 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,956.13 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $193.86 | 2022-2023 | Cequa |
| Apellis Pharmaceuticals, INC. | $146.17 | 2025 | |
| Sight Sciences, INC. | $111.73 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $105.18 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $83.33 | 2022 | |
| Dompe US, INC. | $57.64 | 2025 | Oxervate |
| Alcon Vision LLC | $39.30 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $32.31 | 2025 | Xdemvy |
| Tearlab Corp | $27.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacie Truitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.